Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

Journal of Cell Biology

Volumn 167, Issue 2, 2004, Pages 223-229

  Weis, Sara ^a   Cui, Jianhua ^a   Barnes, Leo ^a   Cheresh, David ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BOSUTINIB; CADHERIN; PROTEIN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; SU 1498; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; GENETIC RESISTANCE; HOST; IN VIVO STUDY; INJECTION; LIVER; LUNG; LUNG ENDOTHELIUM; METASTASIS; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; WILD TYPE;

ANIMALS; ANTIGENS, CD; BETA CATENIN; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; GENE DELETION; GREEN FLUORESCENT PROTEINS; LIVER; LUNG; MICE; MICROSCOPY, ELECTRON; NEOPLASM METASTASIS; NEOPLASMS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-YES; RETROVIRIDAE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; TRANS-ACTIVATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA;

EID: 7244247062     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200408130     Document Type: Article

References (18)

1. Boguslawski, G., P.W. McGlynn, K.A. Harvey, and A.T. Kovala. 2004. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J. Biol. Chem. 279:5716-5724.
2. Boschelli, D.H., F. Ye, Y.D. Wang, M. Dutia, S.L. Johnson, B. Wu, K. Miller, D.W. Powell, D. Yaczko, M. Young, et al. 2001. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 44:3965-3977.
3. Bruns, C.J., M. Shrader, M.T. Harbison, C. Portera, C.C. Solorzano, K.W. Jauch, D.J. Hicklin, R. Radinsky, and L.M. Ellis. 2002. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer. 102:101-108.
4. Eliceiri, B.P., R. Paul, P.L. Schwartzberg, J.D. Hood, J. Leng, and D.A. Cheresh. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell. 4:915-924.
5. Esser, S., M.G. Lampugnani, M. Corada, E. Dejana, and W. Risau. 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:1853-1865.
6. Ferrara, N., H.P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676.
7. Golas, J.M., K. Arndt, C. Etienne, J. Lucas, D. Nardin, J. Gibbons, P. Frost, F. Ye, D.H. Boschelli, and F. Boschelli. 2003. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent anti-proliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63:375-381.
8. Hood, J.D., M. Bednarski, R. Frausto, S. Guccione, R.A. Reisfeld, R. Xiang, and D.A. Cheresh. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2404-2407.
9. Liao, F., Y. Li, W. O'Connor, L. Zanetta, R. Bassi, A. Santiago, J. Overholser, A. Hooper, P. Mignatti, E. Dejana, et al. 2000. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res. 60:6805-6810.
10. Liao, F., J.F. Doody, J. Overholser, B. Finnerty, R. Bassi, Y. Wu, E. Dejana, P. Kussie, P. Bohlen, and D.J. Hicklin. 2002. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 62:2567-2575.
11. Nam, J.S., Y. Ino, M. Sakamoto, and S. Hirohashi. 2002. Src family kinase inhibitor pp2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8:2430-2436.
12. Paul, R., Z.G. Zhang, B.P. Eliceiri, Q. Jiang, A.D. Boccia, R.L. Zhang, M. Chopp, and D.A. Cheresh. 2001. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 7:222-227.
13. Recchia, I., N. Rucci, C. Festuccia, M. Bologna, A.R. MacKay, S. Migliaccio, M. Longo, M. Susa, D. Fabbro, and A. Teti. 2003. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur. J. Cancer. 39:1927-1935.
14. Rowe, D.H., J. Huang, M.L. Kayton, R. Thompson, A. Troxel, K.M. O'Toole, D. Yamashiro, C.J. Stolar, and J.J. Kandel. 2000. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 35:30-32; discussion 32-33.
15. Senger, D.R., L. Van de Water, L.F. Brown, J.A. Nagy, K.T. Yeo, T.K. Yeo, B. Berse, R.W. Jackman, A.M. Dvorak, and H.F. Dvorak. 1993. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303-324.
16. Weis, S., S. Shintani, A. Weber, R. Kirchmair, M. Wood, A. Cravens, H. McSharry, A. Iwakura, Y.S. Yoon, N. Himes, et al. 2004. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113:885-894.
17. Xiang, R., H.N. Lode, C.S. Dolman, T. Dreier, N.M. Varki, X. Qian, K.M. Lo, Y. Lan, M. Super, S.D. Gillies, and R.A. Reisfeld. 1997. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948-4955.
18. Zhang, L., N. Yang, J.R. Garcia, A. Mohamed, F. Benencia, S.C. Rubin, D. Allman, and G. Coukos. 2002. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161:2295-2309.